2HOUSE A A,ELIASZIW M,CATFRAN D C,et al. Effect of B-vi- tamin therapy on progression of diabetic nephropathy: a random- ized controlled trial[ J ]. Jama, 2010,303 ( 16 ) : 1603-1609. 被引量：1
3SABOUNJIAN L A, SHIPLEY J, BRAMAN V, et al. Design and Rationale for Randomized, Doubleblind, Placebo-Contro|led Phase 2 Study to Evaluate the Safety and Etficacy of CTP-499 in Patients With Diabetic Nephropathy (DN)[J]. Advances in Chronic Kid-ney Disease,2012,19(2):123. 被引量：1
4ZHANG M Z, WANG S, YANG S, et al. Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS - / - db/db mice [ J ]. American Journal of Physiology-Renal Physiology, 2012,302(4) : F433. 被引量：1
5Rakitianskaia IA,Riabov SI,Azanchevskaia SV,et al. Role of intrarenal product TNF-alpha in the development of glomeru- lar and tubulointerstitial tissues changes in elderly patients with diabetic nephropathy[J]. Adv Gerontol, 2013,26 (4) : 658-661. 被引量：1
7Cheng H, Harris RC. Renal endothelial dysfunction in diabetic nephropathy. Cardiovasc Hematol Disord Drug Targets,2014,14 (1) :22 -33. 被引量：1
8Kress S, Kostev K, Dippel FW, et al. Micro - and macrovascular outcomes in Type 2 diabetic patients treated with insulin glulisine or human regular insulin:a retrospective database analysis. Int J Clin Pharmacol Ther,2012,50(11) :821 -829. 被引量：1
9Satoh M, Kobayashi S,Kuwabara A,et al. In vivo visualization of glomerular microcirculation and hypedihration in streptozotocin - induced diabetic rats. Microcirculation, 2010, 17 (2) : 103 - 112. 被引量：1
